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Abstract: Ulcerative inflammation of the cornea occurs in the perilimbal cornea, and is 
associated with autoimmune collagen vascular and arthritic diseases. Rheumatoid arthritis is 
the most frequent underlying disease. The tendency for peripheral location is due to the distinct 
morphologic and immunologic characteristics of the limbal conjunctiva, which provides access 
for circulating immune complexes to the peripheral cornea via the capillary network. Deposition 
of immune complexes in the terminal ends of limbal vessels initiates immune-mediated vasculitis, 
and causes inflammatory cell and protein leakage due to vessel wall damage. Development 
of peripheral ulcerative keratitis associated with systemic disease may represent worsening 
of a potentially life-threatening disease. Accompanying scleritis, particularly the necrotizing 
form, is usually observed in severe cases, which may result in corneal perforation and loss of 
vision. Although first-line treatment with systemic corticosteroids is indicated for acute phases, 
immunosuppressive and cytotoxic agents are required for treatment of peripheral ulcerative 
keratitis associated with multisystem disorders. Recently, infliximab, a chimeric antibody 
against proinflammatory cytokine tumor necrosis factor-alpha, was reported to be effective in 
cases refractory to conventional immunomodulatory therapy. The potential side effects of these 
therapies require close follow-up and regular laboratory surveillance.
Keywords: autoimmune disease, peripheral ulcerative keratitis, treatment, tumor necrosis 
factor-alpha
Introduction
Peripheral ulcerative keratitis (PUK) is a form of unilateral crescent-shaped stromal 
inflammation, which involves the juxtalimbal cornea and is characterized by secto-
rial thinning of the affected area. It is always associated with an overlying epithelial 
defect and progressive loss of the corneal stroma (Figure 1A). PUK is often contiguous 
with adjacent conjunctival, episcleral, and scleral inflammation. The presence of such 
adjacent tissue inflammation aggravates the course of PUK and causes potentially 
serious complications, such as perforation of the cornea.1–3 PUK-associated complica-
tions might be prevented with timely diagnosis, detection of the underlying systemic 
inflammatory disease, and proper treatment.
PUK can be associated with numerous systemic diseases and may precede the 
systemic disease, but there is a tendency for it to occur following observation of sys-
temic manifestations. Tauber et al4 reported that PUK was the initial manifestation of 
collagen vascular disease in 50% of cases. Patients with collagen vascular disease-
related PUK often require aggressive systemic treatment to curtail the relentless 
progression of corneal destruction.3,5 This review summarizes the clinical features, 
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pathogenesis, and diseases associated with noninfectious 
PUK, as well as recently developed treatment options.
Etiologic features
PUK may be associated with various ocular and systemic 
infectious and noninfectious diseases. In addition to microbial 
organisms such as bacteria, viruses, fungi, and chlamydia, 
systemic connective tissue, vasculitic autoimmune diseases, 
and dermatologic disorders can cause PUK.2,5–7 Marginal ker-
atitis, also referred to as catarrhal infiltrates, and phlyctenular 
corneal disease are noninfectious inflammatory processes of 
the peripheral cornea. Although clinically distinct entities, 
they share a common pathophysiologic mechanism; they 
develop as a result of hypersensitivity reaction to toxins 
produced by bacteria usually associated with longstanding 
staphylococcal blepharoconjunctivitis.3 Phlyctenules are a 
more severe reaction than catarrhal infiltrates; subepithelial 
inflammatory nodules that first appear in the limbus usu-
ally undergo necrosis, forming an ulcer. Although earlier 
studies reported that there was a strong association between 
tuberculosis and PUK, more recent studies indicate that 
staphylococcal disease is a more common cause.3,6
The most common disorders associated with PUK are sys-
temic collagen vascular diseases, of which rheumatoid arthri-
tis is the most common, accounting for 34% of noninfectious 
PUK cases. Approximately 50% of all noninfectious PUK 
cases have an associated collagen vascular disease.4 Other 
than rheumatoid arthritis, Wegener granulomatosis, relaps-
ing polychondritis, systemic lupus erythematosus, classic 
polyarteritis nodosa and its variants, microscopic polyangiitis 
or Churg–Strauss syndrome can be the cause (Table 1). The 
corneal signs are similar in all collagen vascular inflamma-
tory diseases. Although PUK may be the presenting sign 
of these potentially life-threatening systemic diseases, it 
may develop as a complication of scleritis, especially the 
necrotizing form,4,8 so precise anamnesis, systemic workup, 
and tissue biopsy are required for diagnosis (Figure 2). 
Figure 1 (A) Slit lamp photograph of a patient with juvenile RA demonstrates 
sectorial corneal thinning and overlying epithelial defect, (B) The clinical appearance 
following corneal transplantation for tectonic purpose.
Table 1 Differential diagnosis of peripheral ulcerative keratitis10,16
Ocular Causes
  Bacterial Staphylococcus, Streptococcus 
Gonococcus, Moraxella, 
Hemophilus
  viral Herpes simplex, herpes zoster
  Amebic Acanthamoeba
  Fungal
    Traumatic Chemical, thermal, radiation burn
      Abnormalities of  
eyelids or lashes
Entropion, ectropion, cicatricial, 
exposure, trichiasis,  
lagophthalmos, incomplete blink
      Local, autoimmune Mooren’s ulcer 
Allograft reaction
    Neurologic Neurotrophic keratitis
Systemic
    Autoimmune  
vasculitic diseases
Rheumatoid arthritis, wegener’s 
granulomatosis, relapsing 
polychondritis, systemic lupus 
erythematosus, polyarteritis 
nodosa and variants, Sjögren’s 
syndrome
  Dermatological disorders Acne rosacea, cicatricial 
pemphigoid, Stevens–Johnson 
syndrome
    Inflammatory bowel disease
    Malignancy
    Bacterial Tuberculosis, syphilis, gonorrhea, 
borreliosis, bacillary dysentery
    viral varicella zoster, acquired immune 
deficiency syndrome, hepatitis
Foster et al reported that the mortality rate in untreated 
rheumatoid arthritis patients with PUK/necrotizing scleritis 
is approximately 50% over a 10-year period.9
Pathogenesis
The exact pathophysiologic mechanism of PUK remains 
unclear, but the same pathogenic mechanism is thought 
to occur in all forms of PUK. Research suggest that both 
humoral-mediated and cell-mediated autoimmune processes 
are involved. Reactions to corneal antigens, circulating 
immune complex deposition, and hypersensitivity reactions 
to exogenous antigens are other mechanisms implicated in 
the pathogenesis of PUK.8,10–12
A hypersensitivity reaction to exogenous antigens induces 
catarrhal infiltrate, marginal ulcer, and phyctenule develop-
ment, and has a more favorable prognosis than immune 
disease-related PUK. The peripheral cornea has distinct mor-
phologic and immunologic characteristics that predispose it 
to immune inflammation. Unlike the avascular central cornea, 
the limbus and the peripheral cornea receive a portion of their 
nutrient supply from the capillary arcades, which extend only 
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approximately 0.5 mm into the clear cornea. The vascular 
architecture of the limbus is suitable for accumulation of IgM, 
the first component of complement cascade C1, and other 
high molecular weight molecules and immune complexes in 
the limbus and corneal periphery.13–15 Deposition of immune 
complexes activates the classical pathway of the complement 
system, which in turn results in chemotaxis of inflamma-
tory cells, in particular, neutrophils and macrophages in 
the peripheral cornea. These cells can release collagenases 
and other proteases that destroy the corneal stroma.3,16,17 
Additionally, release of proinflammatory cytokines such as 
interleukin-1 from the inflammatory cells enables stromal 
keratocytes to produce matrix metalloproteinase-1 and 
matrix metalloproteinase-2, which can accelerate the matrix 
destruction process.10
Subconjunctival lymphatics and limbal capillaries in the 
peripheral cornea provide access to the afferent arm of the 
immune system, which facilitates immunologically driven 
corneal inflammation. Moreover, the limbus and conjunctiva 
that are adjacent to PUK have been hypothesized to serve as 
a major reservoir for various effector cells of the immune 
system and proinflammatory cytokines, thereby playing a 
critical role in the immunopathogenesis of PUK.8,18–23
Clinical features
Various ocular manifestations of collagen vascular diseases 
are present in addition to PUK; keratoconjunctivitis sicca is 
the most common, and is clinically evident in 15%–25% of 
patients with rheumatoid arthritis.24 The main symptoms for 
patients are ocular redness, pain, tearing, photophobia, and 
decreased vision secondary to induced astigmatism or corneal 
opacity in advanced cases. Biomicroscopic examination 
shows opacity due to cellular infiltrates within the stroma 
adjacent to the limbus. Later, crescent-shaped corneal ulcers 
develop with breakdown of the overlying epithelium. Varying 
degrees of vascularization and corneal thinning due to   tissue 
loss in the underlying stroma occur as well (Figure 3). 
The depth of peripheral corneal thinning is   variable; in 
severe cases, tissue loss may progress to perforation, with 
or without trauma. Adjacent conjunctival, episcleral, and 
scleral inflammation are also generally apparent. Adjacent 
scleritis is almost always present in patients with Wegener’s 
granulomatosis.4,16,24
It was reported in a review of 47 PUK patients that the 
incidence of nodular or necrotizing scleritis was 64%.4 
Sainz de la Maza et al25 reported that 14% of patients with 
scleritis of all types had PUK versus 41% of patients with 
necrotizing scleritis. The frequency of PUK was reported 
to be 7.4% in a recent study that included 500 patients with 
scleritis and 85 patients with episcleritis. Similar to other 
studies, it was reported that PUK occurred statistically more 
frequently in patients with scleritis than in patients with 
episcleritis and that the presence of necrotizing scleritis 
increases the probability of PUK.26 Most corneal findings 
resolve following appropriate treatment and resolution 
of accompanying scleritis, with resultant scarring and 
  neovascularization. It is thought that surgical trauma triggers 
immune complex-mediated vasculitis in patients with 
collagen vascular disease.25
Differential diagnosis
Some clinical entities, such as Mooren’s ulcer and Terrien’s 
marginal degeneration, share similar clinical features with 
PUK. All are characterized by varying degrees of progressive 
Figure  2  PUK  with  adjacent  necrotizing  scleritis  in  a  patient  with  wegener’s 
granulomatosis, stained with fluorescein.
Figure 3 Crescent-shaped peripheral corneal thinning with superficial vascularization 
and infiltration, which is specific for PUK.
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peripheral corneal thinning and superficial vascularization. 
Unlike PUK and Mooren’s ulcer, inflammation and epithelial 
defects are not hallmarks of Terrien’s marginal degeneration. 
Demarcation from the central cornea with a gray line is 
characteristic of Terrien’s marginal degeneration.27,28
Mooren’s ulcer is a form of PUK which is not associated 
with scleritis. It is idiopathic and occurs at any age, but the 
vast majority of patients are aged .40 years. Mooren’s ulcer 
develops in the absence of any systemic disease that can 
cause PUK. It begins in the peripheral cornea, and spreads 
circumferentially and centrally. The main difference from 
PUK is the severity of pain, which is more intolerable in 
Mooren’s ulcer. It may involve one or both eyes. The central 
border exhibits an overhanging edge and, unlike in PUK, the 
sclera is rarely involved.28–30
Although marginal keratitis and phlyctenular ulcers are 
similar in clinical appearance to PUK, their signs are less 
severe and self-limited. During the ulcerative stages it may be 
difficult to differentiate infectious corneal ulcers, herpes sim-
plex virus keratitis, and phlyctenular and catarrhal ulcers from 
PUK. In contrast with PUK and phlyctenules, catarrhal ulcers 
leave a clear space between the ulcer and the limbus (Figure 4). 
Herpetic infections begin with an epithelial defect, followed 
by an infiltrate, which is the reverse order of that observed in 
marginal keratitis. Additionally, marginal keratitis responds 
rapidly to topical treatment, whereas PUK might worsen due 
to the lack of targeted systemic treatment. Clinicians must be 
able to differentiate these entities from acute infections and 
PUK.3,24 All patients who present with peripheral keratitis 
and ulceration must undergo a detailed personal and family 
history, with specific attention given to collagen vascular and 
other autoimmune diseases. Complete ocular and systemic 
examinations are important for determining the etiology. 
Inflammatory and noninflammatory conditions or infection 
should be considered, in addition to postinfectious disorders, 
abnormalities of the eyelids or lashes, neurologic and derma-
tologic conditions, and malignancies.10,16,25 Specific systemic 
findings may lead ophthalmologists to suspect certain types 
of associated diseases. Laboratory investigations conducted 
according to the findings include complete and differential 
blood cell counts, platelet count, erythrocyte sedimentation 
rate, rheumatoid factor, antinuclear antibody, antineutrophil 
cytoplasmic antibodies, chest X-ray examination, and liver 
enzymes. Additional testing should be performed based 
on the results of these tests. Infectious etiologies should be 
excluded via appropriate cultures, because microbial keratitis 
can rapidly progress and is usually responsive to antibiotic 
therapy.1,8,31–33
Treatment
Treatment of PUK is based on the severity of findings within 
the cornea and the extent of extraocular disease. Treatments 
initiated for systemic autoimmune disease have beneficial 
effects on ocular manifestations. Regardless of the manage-
ment of corneal disease, results will be disappointing unless 
aggressive treatment of the systemic disease is taken into 
consideration. The current treatment strategy for PUK with 
underlying systemic disease is systemic corticosteroids plus 
a cytotoxic agent during the acute phase of the disease. The 
exact cytotoxic agent may differ according to the underlying 
systemic disease.5,6,24,27
The goal of medical treatment for ocular disease is 
to reduce inflammation, promote epithelial healing, and 
minimize stromal loss. Despite improvements in new 
immunomodulatory and biologic agents, the outcome of 
PUK depends primarily on the accompanying disease, and 
timely diagnosis and treatment. In this respect, in addition to 
surgery, the local and systemic stepladder approach should 
be considered.
Local treatment
Local bacterial and viral infections that cause PUK are 
usually relieved with local targeted treatment. Initially oph-
thalmologists should be sure to lubricate the ocular surface 
with preservative-free lubricating agents, because a signifi-
cant number of patients with PUK also suffer from tear film 
abnormalities.6 These agents are also helpful for removing or 
diluting harmful inflammatory proteins and mediators on the 
ocular surface. In patients with marginal ulcerative keratitis 
without an accompanying systemic disease, eyelid hygiene 
Figure 4 Slit lamp appearance of marginal keratitis with characteristic features 
(lesion parallel to limbus and seperated from the limbus by clear cornea).
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and topical corticosteroids can be used and tapered according 
to the clinical response. A topical antibiotic is recommended 
before corticosteroid use.3,6,24
Collagenase inhibitors or collagenase synthetase 
inhibitors, such as topical l% medroxyprogesterone and topi-
cal 20% acetylcysteine, may be of limited benefit in reducing 
additional stromal ulceration. Topical corticosteroids are not 
appropriate in patients with related systemic disease, because 
these drugs inhibit new collagen production and thereby 
increase the risk of perforation.1,4,16,24 Oral tetracycline deriva-
tives may provide additional benefit in preventing further 
stromal loss by decreasing protease activity.34–36
Systemic immune modulation
Glucocorticoids
Systemic corticosteroids are the traditional first-line therapy 
for acute phases of PUK, but alone are often unable to 
inhibit disease progression or overcome the autoimmune 
disease. The usual starting dose is 1 mg/kg/day (maximum 
60 mg/day), followed by a tapering schedule based on clinical 
response. Pulsed methylprednisolone 1 g/day for 3 consecu-
tive days, followed by oral therapy, might be initiated in 
patients with imminent danger of vision loss.1,4,9,24
Immunosuppressive drugs or biologic agents are admin-
istered with or without glucocorticoids in cases refractory 
to glucocorticoids and when glucocorticoid-associated 
adverse effects become an issue. Common complications of 
systemic corticosteroids, such as osteoporosis, exacerbation 
of hypertension and diabetes, electrolyte imbalance, and 
gastrointestinal bleeding, may be avoided with initiation of 
immunosuppressive drugs.1,5,8,10,16 Although steroids have a 
profoundly positive effect on ocular and systemic symptoms, 
they fail to reduce the high mortality rate in patients with 
rheumatoid vasculitis, as reported by Foster et al.9 Therefore, 
the addition of cytotoxic chemotherapy comes up to success-
fully treat these patients.
Immunosuppressives/immunomodulators
To date, there is no universal agreement about which immu-
nosuppressant or modulator should be used for specific 
cases. A review by Jabs et al included an extensive overview 
of the recommended options, doses, and applications for 
immunosuppressive agents.37 Immunosuppressives available 
for use in these cases include antimetabolites, alkylating 
agents, T cell inhibitors, and biologic agents. Methotrexate, 
azathioprine, mycophenolate mofetil, and leflunomide are 
suitable antimetabolite agents. Methotrexate and azathioprine 
are the two most commonly used antimetabolites in cases 
unresponsive to oral corticosteroids and with recalcitrant 
rheumatoid PUK. Oral methotrexate in doses ranging from 
7.5–25 mg/week and azathioprine 1.0–2.5 mg/kg/day have 
been reported to be effective.9,33,37,38 Recent studies indicated 
better inflammatory control and fewer side effects with myco-
phenolate mofetil (1.0 g twice daily) than with methotrexate 
or azathioprine.37,39–41 Moreover, clinical reports suggest that 
leflunomide might be efficacious in the treatment of ocular 
inflammation.42
The alkylating agents, cyclophosphamide and chlorambu-
cil, are suggested for use in severe progressive cases and in 
cases unresponsive to methotrexate or other antimetabolites. 
In a retrospective case series, Messmer and Foster reported 
that cytotoxic immunosuppressive agents are highly effec-
tive in patients resistant to systemic corticosteroids.43 
Cyclophosphamide was reported to be the most effective 
agent in their series; however, methotrexate was reported 
to be very effective with less potential toxicity and was 
suggested as a potential first choice for immunosuppression 
(Figure 5A and B). Cyclophosphamide may be administered 
orally at doses of 1–2 m/kg/day or as pulsed intravenous 
therapy every 3–4 weeks under rheumatologic or internal 
medicine guidance.24,37,38,43–45
Data on the use of cyclosporin A in patients with rheu-
matoid arthritis and severe inflammatory eye disease suggest 
that cyclosporin could be the initial immunosuppressant treat-
ment of choice in idiopathic cases or in those not associated 
with systemic vasculitis, particularly if there are no serious 
concerns about nephrotoxicity.38,44,45 Cases associated with 
systemic vasculitis often require use of more potent immu-
nosuppressives, including cytotoxic (eg, cyclophosphamide) 
or antimetabolite (eg, methotrexate) therapy.38,44,45
Biologic agents
Infliximab (Remicade®; Centocor Ortho Biotech Inc, 
Horsham, PA) was approved for use by the US Food and 
Drug Administration in 1999. Use of infliximab for ocular 
Figure 5 The slit-lamp appearance of PUK contiguous with scleritis, stained with 
fluorescein. (A) Pre-treatment with cyclophosphamide, (B) Post-treatment with 
cyclophosphamide.
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inflammation was first reported in 2001 for patients with 
panuveitis and rheumatoid arthritis-associated scleritis.46,47 
It is currently indicated for treatment of connective tissue or 
vasculitic autoimmune diseases, and accompanying PUK, as 
well as other ocular inflammatory states, such as necrotizing 
scleritis and uveitis.2,48–50 It is a specific, chimeric monoclonal 
antibody against proinflammatory cytokine tumor necrosis 
factor alpha (TNF-α), which stimulates production of the 
matrix metalloproteinases responsible for corneal stromal 
lysis in PUK. It binds both soluble and transmembrane 
TNF-α by blocking its receptor. Cells expressing transmem-
brane TNF-α bound to infliximab may also be susceptible 
to complement-mediated lysis, potentially increasing its 
anti-inflammatory effect.2,51
Dosing of infliximab varies from 3 mg/kg intravenously 
for rheumatoid arthritis to 5 mg/kg intravenously for 
Crohn’s disease, and is administered at weeks 0, 2, and 6, 
and then every 8 weeks for up to 18 months. Improvement 
usually occurs 1–2 weeks after the first infusion. Although 
the optimal frequency and dosing of infliximab for PUK 
and/or corneal perforation have not yet been established, 
a   dosing regimen similar to that used for rheumatoid arthritis 
seems reasonable.2,50,52 The maintenance of remission must 
be weighed against potential adverse events, because the 
long-term efficacy and safety of biologics for use in ocular 
inflammation is unknown.
Before administering infliximab, opportunistic infections 
such as tuberculosis must be ruled out, in addition to abso-
lute contraindications such as congestive heart failure. The 
reported side effects of long-term use include increased risk 
of opportunistic infections, anaphylaxis, diarrhea, cardiac 
failure, and resistance.53 More serious side effects, such as 
lymphoproliferative disorders, malignancy, hepatotoxicity, 
and endogenous endophthalmitis, have been reported. 
Moreover, increased risk of thrombosis was reported, ranging 
from branch retinal vein occlusion to myocardial infarction 
and pulmonary embolus;54–56 therefore, special care must be 
taken when using infliximab and other biologic agents.
Other biologics, including etanercept (Enbrel®; Amgen, 
Thousand Oaks, CA/Wyeth, Philadelphia, PA) and rituximab 
(Rituxan®; Biogen Idec, Cambridge, MA and Genentech, 
South San Francisco, CA), have been used for the treat-
ment of PUK. Etanercept is a human recombinant dimeric 
fusion protein that mimics the effects of naturally occurring 
soluble TNF-α receptors. It has been used for the treatment 
of refractory uveitis, necrotizing scleritis, and keratitis, but 
is less efficacious than infliximab for the treatment of ocular 
inflammation. This may be due to the ability of infliximab to 
bind to membrane-bound TNF-α, in addition to free-floating 
cytokines. Recently, rituximab, a chimeric antibody against 
CD20-α, which depletes B lymphocytes, has been used 
to treat refractory PUK associated with Wegener granu-
lomatosis, in addition to recalcitrant scleritis and anterior 
uveitis.2,31,57,58
Surgical management
Tectonic procedures are required to maintain the integrity 
of the globe (Figure 1B). Options include the use of a tissue 
adhesive, bandage contact lens, lamellar graft, tectonic 
corneal grafting, and amniotic membrane transplantation. 
Use of tissue adhesives is a consideration in patients with 
impending perforation and perforations ,2.0 mm, and 
is followed by application of a bandage contact lens to 
prevent discomfort.16 Corneal grafting should be performed 
following appropriate immunosuppression, but nevertheless 
the outcome is disappointing. Maneo et al reported that 
keratoplasty performed for ulcerative keratitis had the highest 
likelihood of regraft, despite improvements in cytotoxic 
therapy.59 Resection of the perilimbal conjunctiva associated 
with PUK removes immune complexes, decreases production 
of collagenases and proteinases, and consequently promotes 
resolution of inflammation. This treatment is controversial, 
because it is thought that PUK may recur once the conjunctiva 
grows back to the limbus.1,3,4,8,16
In addition to medical treatment, an amniotic membrane 
could be used as a patch or graft to reduce inflammation 
and to promote re-epithelization. It is likely that the biologic 
properties of amniotic membrane downregulate inflamma-
tion due to expression of Fas ligand and human leucocyte 
antigen-G that reduce inflammation and activate suppressor 
T cell mechanisms.60–63
Conclusion
PUK includes a group of corneal infectious and inflam-
matory diseases that usually result in peripheral corneal 
thinning. Inflammatory causes are usually associated with 
life-threatening autoimmune collagen vascular diseases, 
and PUK might be the initial sign of a systemic disease. 
Limbal and conjunctival vessels are prone to deposition of 
circulating immune complexes; increased deposition of these 
complexes increases immunologic activity, which leads to 
vascular occlusion and subsequent leakage of inflamma-
tory cells, along with collagenases and proteases. Usually 
scleritis, specifically the necrotizing form, is present in the 
region adjacent to PUK in patients with underlying systemic 
autoimmune disease. As such, local infectious diseases, either 
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primary or secondary, must be excluded and extensive exami-
nation should not be overlooked for diagnosis of systemic 
disease. The mainstay of treatment is not only controlling 
inflammation of the involved ocular tissues, but may also 
include controlling the underlying systemic vasculitic dis-
ease. Initiation of appropriate immunosuppressive therapy 
with corticosteroids and cytotoxic agents are life-saving. 
Recently, biologic agents that serve as TNF-α antagonists 
by blocking its receptors have become more important in 
the treatment of cases refractory to conventional immuno-
modulatory therapy. Because of the potential side effects 
of these treatments, close follow-up and regular laboratory 
investigations are essential.
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